United Therapeutics Co. (NASDAQ:UTHR) – Research analysts at Leerink Swann issued their FY2019 EPS estimates for shares of United Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will post earnings per share of $7.49 for the year. Leerink Swann currently has a “Market Perform” rating and a $148.00 price objective on the stock.

A number of other analysts have also recently weighed in on the stock. Credit Suisse Group AG started coverage on shares of United Therapeutics in a research note on Thursday, March 16th. They issued an “underperform” rating and a $120.00 target price on the stock. Cowen and Company lowered shares of United Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $140.00 to $121.00 in a research report on Monday, April 3rd. Zacks Investment Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Wedbush reiterated an “outperform” rating and set a $229.00 target price on shares of United Therapeutics in a research report on Wednesday, February 8th. Finally, Standpoint Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, January 19th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $137.42.

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

COPYRIGHT VIOLATION NOTICE: “United Therapeutics Co. (UTHR) to Post FY2019 Earnings of $7.49 Per Share, Leerink Swann Forecasts” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2017/04/21/united-therapeutics-co-uthr-to-post-fy2019-earnings-of-7-49-per-share-leerink-swann-forecasts.html.



Shares of United Therapeutics (NASDAQ:UTHR) traded down 0.17% during mid-day trading on Friday, hitting $121.01. The stock had a trading volume of 640,559 shares. United Therapeutics has a 52 week low of $97.52 and a 52 week high of $169.89. The stock has a 50-day moving average price of $135.24 and a 200 day moving average price of $137.86. The stock has a market cap of $5.44 billion, a P/E ratio of 7.94 and a beta of 1.42.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $4.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.51. The firm earned $409 million during the quarter, compared to the consensus estimate of $415.51 million. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.80 EPS.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,258 shares of the company’s stock in a transaction that occurred on Thursday, April 13th. The shares were sold at an average price of $122.12, for a total value of $153,626.96. Following the completion of the sale, the chief executive officer now owns 1,398 shares of the company’s stock, valued at $170,723.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Tommy G. Thompson sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total transaction of $278,740.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $278,740. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,972 shares of company stock valued at $1,820,179. 7.50% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. Bridgewater Wealth & Financial Management LLC increased its stake in shares of United Therapeutics by 6.4% in the third quarter. Bridgewater Wealth & Financial Management LLC now owns 48,028 shares of the biotechnology company’s stock valued at $5,671,000 after buying an additional 2,896 shares in the last quarter. First Trust Advisors LP boosted its position in shares of United Therapeutics by 92.8% in the third quarter. First Trust Advisors LP now owns 480,971 shares of the biotechnology company’s stock valued at $56,793,000 after buying an additional 231,502 shares during the last quarter. Selway Asset Management boosted its position in shares of United Therapeutics by 399.3% in the third quarter. Selway Asset Management now owns 18,475 shares of the biotechnology company’s stock valued at $2,182,000 after buying an additional 14,775 shares during the last quarter. APG Asset Management N.V. boosted its position in shares of United Therapeutics by 73.7% in the third quarter. APG Asset Management N.V. now owns 416,892 shares of the biotechnology company’s stock valued at $49,227,000 after buying an additional 176,900 shares during the last quarter. Finally, Virginia Retirement Systems ET AL boosted its position in shares of United Therapeutics by 5.6% in the third quarter. Virginia Retirement Systems ET AL now owns 120,000 shares of the biotechnology company’s stock valued at $14,170,000 after buying an additional 6,400 shares during the last quarter.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

5 Day Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related stocks with our FREE daily email newsletter.